Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Molecular Psychiatry

• Publication date

  1997-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.mp.4000249PMID 9106238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment

  2005cited by this paper
• The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity

  2005cited by this paper
• Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release

  2005cited by this paper
• D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

  2004cited by this paper
• The putative schizophrenia locus on chromosome 6p: a brief overview of the linkage studies.

  1996cited by this paper
• Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia

  1996cited by this paper
• Dopamine D4 receptor variant in Africans, D4valine194glycine, is insensitive to dopamine and clozapine: report of a homozygous individual.

  1996cited by this paper
• A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.

  1996cited by this paper
• Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders.

  1996cited by this paper
• Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia.

  1996cited by this paper
• Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system.

  1996cited by this paper
• Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia.

  1996cited by this paper
• Up‐regulation of D3 dopamine receptor mRNA by neuroleptics

  1996cited by this paper
• Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

  1996cited by this paper
• D2-Family receptor distribution in human postmortem tissue: an autoradiographic study

  1995cited by this paper
• A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.

  1995cited by this paper
• Schizophrenia. All out for chromosome six.

  1995cited by this paper
• Association study of dopamine D3 receptor gene and schizophrenia.

  1995cited by this paper
• The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects

  1995cited by this paper
• Genetic basis of schizophrenia.

  1995cited by this paper
• Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors

  1995cited by this paper
• Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia.

  1994cited by this paper
• Failure to find evidence for linkage or association between the dopamine D3 receptor gene and schizophrenia.

  1994cited by this paper
• Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.

  1994cited by this paper
• The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain

  1994cited by this paper
• Distribution of the MscI polymorphism of the dopamine D3 receptor in an Italian psychotic population.

  1994cited by this paper
• Dopamine D2 and D3 receptors inhibit dopamine release.

  1994cited by this paper
• Dopamine receptor pharmacology.

  1994cited by this paper
• Further evidence of no linkage between schizophrenia and the dopamine D3 receptor gene locus.

  1994cited by this paper
• No evidence of linkage between schizophrenia and D3 dopamine receptor gene locus in Icelandic pedigrees.

  1993cited by this paper
• No association between schizophrenia and homozygosity at the D3 dopamine receptor gene.

  1993cited by this paper
• A study of the association between schizophrenia and the dopamine D3 receptor gene

  1993cited by this paper
• Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia?

  1993cited by this paper
• Clozapine and sulpiride up-regulate dopamine D3 receptor mRNA levels.

  1993cited by this paper
• Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene

  1993cited by this paper
• Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

  1993cited by this paper
• Excess of homozygosity at the dopamine D3 receptor gene in schizophrenia not confirmed.

  1993cited by this paper
• Diabetes and development of tardive dyskinesia.

  1993cited by this paper
• Gender differences in tardive dyskinesia: a critical review of the literature.

  1992cited by this paper
• Association between schizophrenia and homozygosity at the dopamine D3 receptor gene.

  1992cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system.

  1991cited by this paper
• Chromosomal localization of the human D3 dopamine receptor gene

  1991cited by this paper
• Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia.

  1991cited by this paper
• Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

  1990cited by this paper
• [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome].

  1990cited by this paper
• Genetic mapping of common diseases: the challenges of manic-depressive illness and schizophrenia.

  1990cited by this paper
• The Nithsdale Schizophrenia Survey V. Follow-up of Tardive Dyskinesia at 3-1/2 years

  1986cited by this paper
• Possible association between tardive dyskinesia and altered carbohydrate metabolism.

  1985cited by this paper
• Tardive dyskinesia: a two-year follow-up study.

  1984cited by this paper
• Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis

  1984cited by this paper
• One Year Follow-Up of Tardive Dyskinesia

  1983cited by this paper
• The Nithsdale Schizophrenia Survey: II. Abnormal Movements

  1982cited by this paper
• Tardive dyskinesia: prevalence and risk factors, 1959 to 1979

  1982cited by this paper
• The Nithsdale Schizophrenia Survey: I. Psychiatric and Social Handicaps

  1982cited by this paper
• Incidence and severity of tardive dyskinesia increase with age.

  1982cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Familial tardive dyskinesia.

  1981cited by this paper
• Familial occurrence of tardive dyskinesia.

  1981cited by this paper
• Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

  1980cited by this paper
• Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

  1976cited by this paper
• The pharmacology of tardive dyskinesias.

  1973cited by this paper
• Pharmacologically induced behavioural supersensitivity to apomorphine.

  1973cited by this paper

• Arrestin-3 Agonism at Dopamine D3 Receptors Defines a Subclass of Second-Generation Antipsychotics That Promotes Drug Tolerance

  2023cites this paper
• Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications

  2023cites this paper
• Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

  2022cites this paper
• Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies

  2022cites this paper
• Possible involvement of apoptosis in the antipsychotics side effects: A mini‐review

  2022cites this paper
• Arrestin-3 agonism at D3 dopamine receptors defines a subclass of second generation antipsychotics that promotes drug tolerance

  2022cites this paper
• “Evaluating and Managing Tardive Dyskinesia in the Older Adult”

  2021cites this paper
• Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside

  2021cites this paper
• Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox.

  2021cites this paper
• Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson’s disease

  2021cites this paper
• Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients

  2021cites this paper
• Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports

  2020cites this paper
• Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia

  2019cites this paper
• Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia

  2019cites this paper
• Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly

  2018cites this paper
• Pharmacogenetics and levodopa induced motor complications

  2018cites this paper
• Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.

  2018cites this paper
• Motor dysfunction as research domain in the period preceding manifest schizophrenia: A systematic review

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Genetics of tardive dyskinesia: Promising leads and ways forward.

  2018cites this paper
• Tardive Dystonia due to D2 Antagonists and Other Agents

  2018cites this paper
• New findings in pharmacogenetics of schizophrenia

  2018cites this paper
• Stratification of the risk of developing tardive drug-induced complications

  2017cites this paper
• Orofacial Dystonias and Dyskinesias

  2017cites this paper
• Orofacial Disorders

  2017cites this paper
• Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease

  2017cites this paper
• Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice.

  2016cites this paper
• Pharmacogenetics of tardive dyskinesia: an updated review of the literature.

  2016cites this paper
• The Genetics of Antipsychotic Response: Pharmacogenetic and Pharmacogenomic Investigations and Clinical Applications

  2016cites this paper
• What happens in Norwegian epidemiological research on mental health? A contemporary perspective

  2015influential citation
• Personalized treatment of schizophrenia in everyday clinical practice: reality or fiction?

  2015cites this paper
• Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis

  2015cites this paper
• A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Pharmacogenetics of antipsychotic treatment in schizophrenia.

  2014cites this paper
• Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

  2014cites this paper
• Drug-Induced Chorea

  2014cites this paper
• Wnt signaling pathway in schizophrenia.

  2014cites this paper
• Pharmacogenetics of Antipsychotics

  2014cites this paper
• Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model

  2014cites this paper
• Personalized medicine in psychiatry: problems and promises

  2013cites this paper
• There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients

  2013cites this paper
• Deep Brain Stimulation of the Subthalamic and Entopeduncular Nuclei in an Animal Model of Tardive Dyskinesia

  2013cites this paper
• Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

  2013influential citation
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations.

  2012cites this paper
• Relevance of animal models to human tardive dyskinesia

  2012cites this paper
• Drug-induced movement disorders in long-stay psychiatric patients : genetic and non-genetic risk factors : a prospective study

  2012influential citation
• Farmacogenética de las reacciones adversas a los antipsicóticos en pacientes con esquizofrenia

  2012cites this paper
• Radioligand Binding to Brain Dopamine and Serotonin Receptors and Transporters in Parkinson's Disease: Relation to Gene Polymorphisms

  2012cites this paper
• Allele and Genotype Frequencies of Serotonin and Dopamine Transporter and Receptor Polymorphisms in a Norwegian Population

  2011cites this paper
• The role and impact of SNPs in pharmacogenomics and personalized medicine.

  2011cites this paper
• The tardive syndromes

  2011cites this paper
• Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

  2011cites this paper
• Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia

  2011cites this paper
• Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease

  2011cites this paper
• Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

  2011cites this paper
• DHEA and Dyskinesias

  2011cites this paper
• Pharmacogenomic testing to guide treatment using antipsychotic medications

  2011cites this paper
• Genetics of Antipsychotic-induced Side Effects and Agranulocytosis

  2011cites this paper
• Genetics of tardive dyskinesia.

  2011cites this paper
• DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers

  2011cites this paper
• Support for association of HSPG2 with tardive dyskinesia in Caucasian populations

  2011cites this paper
• Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

  2011cites this paper
• Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives.

  2010cites this paper
• Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia

  2010influential citation
• Dopamine Receptor Genetics in Neuropsychiatric Disorders

  2010cites this paper
• Pharmacogenetics and schizophrenia.

  2010cites this paper
• Pharmacogenetic considerations in the treatment of psychiatric disorders

  2010cites this paper
• Sertindole in the treatment of tardive dyskinesia in a patient with genetically abnormal dopamine D3 receptors

  2010cites this paper
• Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.

  2010cites this paper
• Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Progress in Genetic Studies of Schizophrenia

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Tardive dyskinesia in a patient treated with quetiapine

  2009cites this paper
• Association study of serotonergic gene variants with antipsychotic-induced adverse reactions

  2009cites this paper
• Pharmacological profile and pharmacogenetic approaches of antipsychotics

  2009cites this paper
• A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms

  2009cites this paper
• Association study between glutathione S‐transferase GST‐M1, GST‐T1, and GST‐P1 polymorphisms and tardive dyskinesia

  2009cites this paper
• Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.

  2009cites this paper
• Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder.

  2009influential citation
• The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta‐analysis

  2009cites this paper
• No association between the DRD3 Ser9Gly polymorphism and schizophrenia.

  2008cites this paper
• Pharmacogenomics Applications in Psychiatric Disorders

  2008cites this paper
• Effects of the Dopamine D3 Receptor (DRD3) Gene Polymorphisms on Risperidone Response: A Pharmacogenetic Study

  2008cites this paper
• Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.

  2008cites this paper
• [Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects].

  2008cites this paper
• La pharmacorésistance des épilepsies partielles : épidémiologie, mécanismes, pharmacogénétique, perspectives thérapeutiques

  2008cites this paper
• Gene Association Studies of Schizophrenia and Tardive Dyskinesia

  2008cites this paper
• No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.

  2008cites this paper
• Orofacial Movement Disorders.

  2008cites this paper
• Orofacial movement disorders.

  2008cites this paper
• Drug-induced tardive motor syndromes.

  2007cites this paper
• No evidence for an association between G protein β3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia

  2007cites this paper
• Pharmacogenetics and schizophrenia.

  2007cites this paper
• Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

  2007cites this paper
• Pharmacogenetics and Pharmacogenomics in Psychiatry: Clinical Applications

  2007cites this paper
• Lack of association between dopamine D3 receptor Ser9Gly polymorphism and schizophrenia in Han Chinese population

  2007cites this paper
• Association of genetic variants and the susceptibility to abnormal involuntary movements and tardive dyskinesia (TD) in Xhosa schizophrenia patients

  2007cites this paper